<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159947</url>
  </required_header>
  <id_info>
    <org_study_id>SPT-07A</org_study_id>
    <nct_id>NCT05159947</nct_id>
  </id_info>
  <brief_title>SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial</brief_title>
  <acronym>SPAIR-2</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Trial of the Efficacy and Safety of SPT-07A Injection in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Huyun New Drug Research and Development Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Canming Pharmaceutical Technology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Haijinge Pharmaceutical Technology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiang Yang NO.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan NO. 4 hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an University Xianyang hospital Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hengshui People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inner Mongolia Baogang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daqing oilfield general hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meihekou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Taizhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Taizhou hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanhua University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated hospital of jining medical college</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neijiang Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tancheng first people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taian Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang nanshai hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dezhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanyang Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deyang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fukuang General Hospital of Liaoning health industry group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Gaoxin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiaxing First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Zhangzhou hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daqing people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hainan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qujing first people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Qiqihar Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Hebei North University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linfen Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuancheng people's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shihezi University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jingzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huanggang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sinopharm Dongfeng General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changjiang Shipping General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enshi Tujia and Miao Autonomous Prefecture Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangtan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel controlled&#xD;
      clinical trial in Chinese patients with acute ischemic stroke. Objective to evaluate the&#xD;
      efficacy and safety of SPT-07A injection compared with placebo in the treatment of patients&#xD;
      with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population of this study is patients with acute ischemic stroke within 48 hours.&#xD;
      All potential participants must provide informed consent, and those who provide informed&#xD;
      consent will enter the screening (- 48 ~ 0h), and the screening qualification will be&#xD;
      evaluated according to the inclusion criteria. The eligible subjects will enter the treatment&#xD;
      period (day 1-7) and will be randomly assigned to the experimental group (SPT-07A injection&#xD;
      group) or the control group (placebo group).&#xD;
&#xD;
      During the treatment period, all subjects will receive SPT-07A injection or placebo by&#xD;
      intravenous drip, twice a day for 7 consecutive days. During the treatment, all subjects need&#xD;
      to receive basic treatment: citicoline sodium injection 0.25g, intravenous drip slowly, once&#xD;
      a day, continuous administration for 7 days. According to the Chinese guidelines for the&#xD;
      diagnosis and treatment of acute ischemic stroke (2018), the patients were given&#xD;
      antihypertensive, hypoglycemic, lipid-lowering, anticoagulant or mannitol. All subjects were&#xD;
      not allowed to receive interventional therapy (mechanical thrombectomy or stent implantation,&#xD;
      etc.), thrombolysis (such as rtPA and urokinase), other cerebrovascular dilators (such as&#xD;
      Butylphthalide, Flunarizine, Nicardipine and Nimodipine, etc.), other neuroprotective agents&#xD;
      (such as Edaravone,etc., except citicoline) during the whole trial period. After the end of&#xD;
      the treatment period (the 7th day), the subjects will enter the follow-up period (the&#xD;
      8th-90th day).&#xD;
&#xD;
      During the follow-up period, subjects need to be followed up twice (30th day ± 3 days, 90th&#xD;
      day ± 7 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Good outcome at 90 days</measure>
    <time_frame>at day 90 (±7)</time_frame>
    <description>proportion of subjects with a modified Rankin Scale (mRS) ≤ 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with a modified Rankin Scale (mRS) ≤ 2 at day 90(±7)</measure>
    <time_frame>at day 90(±7)</time_frame>
    <description>proportion of subjects with a modified Rankin Scale (mRS) ≤ 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale (NIHSS) at day 8(+1)</measure>
    <time_frame>at day 8(+1)</time_frame>
    <description>proportion of subjects with a National Institute of Health stroke scale (NIHSS) 0-1 or mean improvement value from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI) at day 90(±7)</measure>
    <time_frame>at day 90(±7)</time_frame>
    <description>proportion of subjects with a Barthel Index (BI) ≥95</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS) at day 8(+1), 30(±3) and day 90(±7)</measure>
    <time_frame>at day 8(+1), 30(±3) and day 90(±7)</time_frame>
    <description>score of modified Rankin Scale (mRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale (NIHSS) at day 8(+1), 30(±3) and day 90(±7)</measure>
    <time_frame>at day 8(+1), 30(±3) and day 90(±7)</time_frame>
    <description>score of National Institute of Health stroke scale (NIHSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI) at day 8(+1), 30(±3) and day 90(±7)</measure>
    <time_frame>at day 8(+1), 30(±3) and day 90(±7)</time_frame>
    <description>score of Barthel Index (BI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1112</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Test group (SPT-07A injection group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (placebo group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPT-07A injection</intervention_name>
    <description>20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.</description>
    <arm_group_label>Test group (SPT-07A injection group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.</description>
    <arm_group_label>Control group (placebo group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged 18 to 85 years;&#xD;
&#xD;
          2. According to the Key points for diagnosis of various major cerebrovascular diseases in&#xD;
             China 2019 and combined with the experience of clinicians, patients with ischemic&#xD;
             stroke were diagnosed;&#xD;
&#xD;
          3. From &quot;the last time that looks normal&quot; to the beginning of drug treatment ≤ 48 hours.&#xD;
             When the onset time of symptoms can not be accurately obtained after awakening stroke&#xD;
             or due to aphasia, disturbance of consciousness and other reasons, the final time of&#xD;
             normal performance of patients should be taken as the criterion.&#xD;
&#xD;
          4. First onset of ischemic stroke or prestroke with mRS of 0 or 1;&#xD;
&#xD;
          5. A National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20, and a&#xD;
             total score of upper and lower limbs ≥2 on motor deficits;&#xD;
&#xD;
          6. Capable of understanding the purpose and risk of the study and has signed, in writing,&#xD;
             the informed consent form (ICF). If the subject is not capable of this at the time of&#xD;
             enrollment, a legally authorized representative (LAR) will provide written informed&#xD;
             consent in accordance with all regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious disturbance of consciousness (NIHSS 1a ≥2 score);&#xD;
&#xD;
          2. Based on the opinion of the Investigator, the posterior circulation symptoms like&#xD;
             ataxia in stroke patients are caused by posterior circulation ischemia, such as&#xD;
             brainstem or cerebellum;&#xD;
&#xD;
          3. Neuroimaging (CT/MRI) revealed intracranial hemorrhagic diseases (such as cerebral&#xD;
             hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, ventricular&#xD;
             hemorrhage, traumatic cerebral hemorrhage, etc.);&#xD;
&#xD;
          4. Rapidly improving or resolving symptoms, suggesting a possible transient ischemic&#xD;
             attack (TIA) rather than a qualifying stroke;&#xD;
&#xD;
          5. Subjects who are ready to undergo or have undergone intravenous thrombolysis, or&#xD;
             endovascular therapy in 90 days from onset;&#xD;
&#xD;
          6. Renal insufficiency: Serum creatinine &gt; 2.5 times the upper limit of normal value, or&#xD;
             other known serious renal insufficiency diseases;&#xD;
&#xD;
          7. Liver function damage: ALT and AST &gt; 2.5 times the upper limit of normal value, or&#xD;
             other known liver diseases such as acute and chronic hepatitis, cirrhosis, etc.;&#xD;
&#xD;
          8. Poorly controlled hypertension, with systolic blood pressure (≥ 180 mmHg) and/or&#xD;
             diastolic blood pressure ( ≥110 mmHg);&#xD;
&#xD;
          9. Subjects with heart rate &lt; 40 beats/min and/or heart rate &gt; 120 beats/min; 2-degree or&#xD;
             3-degree cardiac block without pacemaker or other malignant arrhythmia; acute&#xD;
             myocardial infarction or interventional therapy in the past month, patients with heart&#xD;
             failure (according to NYHA grade III-IV);&#xD;
&#xD;
         10. Patients with status epilepticus who are unable to cooperate or unwilling to cooperate&#xD;
             due to other organic mental disorders and moderate or severe cognitive impairment;&#xD;
&#xD;
         11. Subjects with malignant tumors, serious diseases of the blood, digestive or other&#xD;
             systems or hemophilia and the expected survival time is not more than 3 months;&#xD;
&#xD;
         12. Female subjects who are pregnant, lactating/breast-feeding, or plan to become&#xD;
             pregnant;&#xD;
&#xD;
         13. Allergic constitution, or allergic to experimental drugs, analogous drugs or basic&#xD;
             treatment drugs;&#xD;
&#xD;
         14. Received treatment with any other investigational drug within 30 days before Baseline,&#xD;
             or is currently participating in another clinical study;&#xD;
&#xD;
         15. Any other reasons that, in the opinion of the investigator, make the subject&#xD;
             unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Hu, Dr. or PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Wan, Dr.</last_name>
    <phone>+86-15872394527</phone>
    <email>wanyanalan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Wan, Dr.</last_name>
      <phone>+86-15872394527</phone>
      <email>wanyanalan@163.com</email>
    </contact>
    <investigator>
      <last_name>Bo Hu, Dr./PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Hu Bo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

